{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:51:06Z","timestamp":1793242266780,"version":"4.5.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec id=\"ab-ioi250076-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>A single respiratory syncytial virus (RSV) vaccine dose is recommended for older adults and persons at increased risk for severe RSV. Clinical information on the long-term effectiveness of RSV vaccines is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250076-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the effectiveness of RSV vaccination over 2 respiratory illness seasons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250076-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This target trial emulation used data from the Veterans Health Administration and included veterans 60 years and older who were eligible for RSV vaccination from September 2023 to March 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250076-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>A single dose of a recombinant stabilized prefusion F protein RSV vaccine vs no RSV vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250076-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Eligible vaccine recipients were matched with up to 4 unvaccinated individuals in 7 monthly, nested sequential trials from September 1, 2023, to March 31, 2024. Outcomes were ascertained through March 31, 2025. The primary outcome was any positive RSV test result from day 14 following the matched index date. Secondary outcomes included RSV-associated emergency department or urgent care visits, hospitalizations, or intensive care unit admissions. Vaccine effectiveness was estimated as 100\u2009\u00d7\u2009(1 \u2013 risk ratio).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250076-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 288\u202f111 vaccinated individuals were matched to 1\u202f075\u202f893 unique control individuals, weighted equally to represent 576\u202f222 individuals, and followed up for a median of 15.8 months (IQR, 14.5-17.0). Across both groups, 544\u202f364 of 576\u202f222 veterans (94.5%) were male, and the median age was 76.1 years (IQR, 71.6-80.0). Vaccine effectiveness against documented RSV infections decreased from 82.5% (95% CI, 77.5%-86.9%) over 0 to 1 month to 59.4% (95% CI, 55.6%-63.5%) over 0 to 18 months of follow-up. During the same period, effectiveness decreased from 84.9% (95% CI, 78.4%-90.2%) to 60.5% (95% CI, 56.4%-65.7%) for emergency visits and 88.9% (95% CI, 77.9%-95.7%) to 57.3% (95% CI, 47.3%-66.4%) for hospitalizations and was 92.5% (95% CI, 61.1%-100.0%) and 71.9% (95% CI, 42.8%-90.0%) for intensive care unit admissions. Among immunocompromised individuals, protection against documented infections decreased from 75.2% (95% CI, 52.5%-89.3%) to 39.7% (95% CI, 23.9%-52.7%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250076-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The study found that RSV vaccination was effective in preventing RSV illness and associated health care use but that protection decreased over 2 seasons. Reductions were most notable among immunocompromised persons, suggesting the need to review whether additional vaccine doses may benefit certain risk groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.6355","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:31:12Z","timestamp":1764001872000},"page":"78","source":"Crossref","is-referenced-by-count":22,"title":["Durability of Respiratory Syncytial Virus Vaccine Effectiveness Among US Veterans"],"prefix":"10.1001","volume":"186","author":[{"given":"Kristina L.","family":"Bajema","sequence":"first","affiliation":[{"name":"Veterans Affairs Portland Health Care System, Portland, Oregon"},{"name":"Division of Infectious Diseases, Department of Medicine, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Bui","sequence":"additional","affiliation":[{"name":"Veterans Affairs Portland Health Care System, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yan","sequence":"additional","affiliation":[{"name":"Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center, Veterans Affairs Connecticut Health Care System, West Haven"},{"name":"Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuli","family":"Li","sequence":"additional","affiliation":[{"name":"Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center, Veterans Affairs Connecticut Health Care System, West Haven"},{"name":"Biomedical Informatics & Data Science, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nallakkandi","family":"Rajeevan","sequence":"additional","affiliation":[{"name":"Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center, Veterans Affairs Connecticut Health Care System, West Haven"},{"name":"Biomedical Informatics & Data Science, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vergun","sequence":"additional","affiliation":[{"name":"Veterans Affairs Portland Health Care System, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyshnika","family":"Sriskantharajah","sequence":"additional","affiliation":[{"name":"Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise M.","family":"Hynes","sequence":"additional","affiliation":[{"name":"Center of Innovation to Improve Veteran Involvement in Care, Veterans Affairs Portland Health Care System, Portland, Oregon"},{"name":"Health Management and Policy, College of Health, Center for Quantitative Life Sciences, Oregon State University, Corvallis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Berry","sequence":"additional","affiliation":[{"name":"Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center, Veterans Affairs Connecticut Health Care System, West Haven"},{"name":"Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Mo","family":"Lin","sequence":"additional","affiliation":[{"name":"Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center, Veterans Affairs Connecticut Health Care System, West Haven"},{"name":"Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Aslan","sequence":"additional","affiliation":[{"name":"Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center, Veterans Affairs Connecticut Health Care System, West Haven"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Ioannou","sequence":"additional","affiliation":[{"name":"Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington"},{"name":"Divisions of Gastroenterology, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"ioi250076r1","doi-asserted-by":"publisher","first-page":"l5021","DOI":"10.1136\/bmj.l5021","article-title":"Respiratory syncytial virus infection in adults.","volume":"366","author":"Nam","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"ioi250076r2","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13031","article-title":"Respiratory syncytial virus disease burden in adults aged 60?years and older in high-income countries: a systematic literature review and meta-analysis.","volume":"17","author":"Savic","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"issue":"2","key":"ioi250076r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0527","article-title":"Mortality associated with influenza and respiratory syncytial virus in the US, 1999-2018.","volume":"5","author":"Hansen","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"11","key":"ioi250076r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.44756","article-title":"Burden of respiratory syncytial virus\u2013associated hospitalizations in US adults, October 2016 to September 2023.","volume":"7","author":"Havers","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"32","key":"ioi250076r5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged =60 years: updated recommendations of the advisory committee on immunization practices\u2014United States, 2024.","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"ioi250076r7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults.","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"ioi250076r8","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults.","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"ioi250076r9","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV preF vaccine in older adults.","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"ioi250076r10","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/cid\/ciae010","article-title":"Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.","volume":"78","author":"Ison","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"6","key":"ioi250076r11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S2213-2600(25)00048-7","article-title":"Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.","volume":"13","author":"Ison","year":"2025","journal-title":"Lancet Respir Med"},{"key":"ioi250076r12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf061","article-title":"Efficacy, immunogenicity, and safety of the bivalent respiratory syncytial virus (RSV) prefusion F vaccine in older adults over 2 RSV seasons.","author":"Walsh","journal-title":"Clinical Infectious Diseases"},{"key":"ioi250076r13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00796-5","article-title":"Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study.","author":"Bajema","journal-title":"The Lancet Infectious Diseases"},{"issue":"8","key":"ioi250076r14","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"7","key":"ioi250076r16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236554","article-title":"Automated EHR score to predict COVID-19 outcomes at US Department of Veterans Affairs.","volume":"15","author":"Osborne","year":"2020","journal-title":"PLoS ONE"},{"issue":"1","key":"ioi250076r18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward.","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"issue":"12","key":"ioi250076r19","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models.","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"3","key":"ioi250076r20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10654-019-00494-6","article-title":"Principles of confounder selection.","volume":"34","author":"VanderWeele","year":"2019","journal-title":"Eur J Epidemiol"},{"issue":"387","key":"ioi250076r22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","article-title":"Reducing bias in observational studies using subclassification on the propensity score.","volume":"79","author":"Rosenbaum","year":"1984","journal-title":"J Am Stat Assoc"},{"issue":"25","key":"ioi250076r23","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"10","key":"ioi250076r25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1001\/jamainternmed.2023.3587","article-title":"Late mortality after COVID-19 infection among US veterans vs risk-matched comparators: a 2-year cohort analysis.","volume":"183","author":"Iwashyna","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"12","key":"ioi250076r26","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1089\/aid.2014.0037","article-title":"Worth the weight: using inverse probability weighted Cox models in AIDS research.","volume":"30","author":"Buchanan","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ioi250076r27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.15896","article-title":"RSV vaccine effectiveness against hospitalization among US adults aged 60 years or older during 2 seasons.","author":"Surie","journal-title":"JAMA"},{"key":"ioi250076r24","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511802843","volume-title":"Bootstrap Methods and Their Application","author":"Davison","year":"1997"},{"key":"ioi250076r6","unstructured":"US Centers for Disease Control and Prevention. Respiratory syncytial virus (RSV) vaccination coverage and intent for vaccination, adults 75 years and older and adults 60\u201374 years with high-risk conditions, United States. Accessed June 8, 2025. https:\/\/www.cdc.gov\/rsvvaxview\/dashboard\/adults-60-coverage-intent.html"},{"key":"ioi250076r15","unstructured":"US Centers for Disease Control and Prevention. Immunization (IZ) gateway. Accessed November 3, 2024. https:\/\/www.cdc.gov\/iis\/iz-gateway\/index.html"},{"key":"ioi250076r17","unstructured":"US Department of Veterans Affairs. Veterans integrated services networks (VISNs). Accessed September 14, 2024. https:\/\/www.va.gov\/HEALTH\/visns.asp?msclkid=5dbaec00d09811ec9cf829deb0e7f5ef"},{"key":"ioi250076r21","unstructured":"Randall? M, Stern? A, Su? Y. Five ethical risks to consider before filling missing race and ethnicity data. Accessed September 14, 2024. https:\/\/www.urban.org\/sites\/default\/files\/publication\/103830\/five-ethical-risks-to-consider-before-filling-missing-race-and-ethnicity-data-workshop-findings_0.pdf"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2841272\/jamainternal_bajema_2025_oi_250076_1766507945.64244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:01:01Z","timestamp":1767628861000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2841272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.6355","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}